Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina

Phase 3 Completed 1004 enrolled Tasly Pharmaceuticals, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This phase III study is designed as a double blind, randomized, multi-nation, multi-center, placebo controlled clinical research, which aims to evaluate the safety and efficacy of Dantonic® (T89) in patients with chronic stable angina pectoris.

Timeline

Start: 2012-08
Primary completion: 2016-12
Completion: 2016-12

Publications

Shi Y, Liu D, Yuan J, Yan L, Zhan Z, Pan D, Lin L, Mu B. Compound Danshen Dripping Pills Prevented Leptin Deficiency-Induced Hepatic ER Stress, Stimulated Autophagy, and Improved Insulin Resistance of ob/ob Mice. Evid Based Complement Alternat Med. 2020 Jul 3;2020:5368657. doi: 10.1155/2020/5368657. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sanqi+Bingpian	Unknown	225 mg	Oral
Subject	T89	Traditional medicine (herbal / TCM)	150 mg	Oral
Subject	T89	Traditional medicine (herbal / TCM)	225 mg	Oral

Indications

No indication recorded.